CN102292349B - 稳定的生长激素化合物 - Google Patents

稳定的生长激素化合物 Download PDF

Info

Publication number
CN102292349B
CN102292349B CN201080005067.4A CN201080005067A CN102292349B CN 102292349 B CN102292349 B CN 102292349B CN 201080005067 A CN201080005067 A CN 201080005067A CN 102292349 B CN102292349 B CN 102292349B
Authority
CN
China
Prior art keywords
growth hormone
hormone compound
hgh
amino acid
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080005067.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292349A (zh
Inventor
O.H.奥尔森
J.布雷因霍尔特
C.B.席奥特
H.德姆思
L.诺斯科夫-劳里特森
P.泰格森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN102292349A publication Critical patent/CN102292349A/zh
Application granted granted Critical
Publication of CN102292349B publication Critical patent/CN102292349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201080005067.4A 2009-01-22 2010-01-22 稳定的生长激素化合物 Active CN102292349B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09151108 2009-01-22
EP09151108.9 2009-01-22
US14811909P 2009-01-29 2009-01-29
US61/148119 2009-01-29
PCT/EP2010/050725 WO2010084173A1 (en) 2009-01-22 2010-01-22 Stable growth hormone compounds

Publications (2)

Publication Number Publication Date
CN102292349A CN102292349A (zh) 2011-12-21
CN102292349B true CN102292349B (zh) 2016-04-13

Family

ID=40521462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080005067.4A Active CN102292349B (zh) 2009-01-22 2010-01-22 稳定的生长激素化合物

Country Status (14)

Country Link
US (1) US8513192B2 (https=)
EP (1) EP2389389B1 (https=)
JP (2) JP5816097B2 (https=)
KR (1) KR20110122100A (https=)
CN (1) CN102292349B (https=)
AU (1) AU2010207725B2 (https=)
CA (1) CA2747825A1 (https=)
ES (1) ES2542202T3 (https=)
IL (1) IL213686A0 (https=)
MX (1) MX2011007736A (https=)
RU (1) RU2539797C2 (https=)
TW (1) TWI504405B (https=)
WO (1) WO2010084173A1 (https=)
ZA (1) ZA201105419B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
EP2595661A1 (en) * 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CA3205469A1 (en) * 2020-12-18 2022-06-23 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891840A (en) * 1988-08-24 1999-04-06 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
US5101018A (en) * 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
DE69333718T2 (de) 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5736356A (en) 1994-01-28 1998-04-07 Ajinomoto Co., Inc. Transglutaminase originating from Crassostrea gigas
NZ291414A (en) 1994-08-26 1998-05-27 Novo Nordisk As Microbial transglutaminases and methods of production using fungi and dna constructs
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
CA2208730A1 (en) 1995-01-19 1996-07-25 Novo Nordisk A/S Transglutaminases from oomycetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) * 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
ES2332931T3 (es) * 1997-06-25 2010-02-15 Merck Serono Sa Analogos de hormonas glicoproteinicas entrelazadas por disulfuro, su preparacion y uso.
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1198565A1 (en) 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ES2331909T3 (es) * 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
WO2003044056A2 (en) 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
CA2480858A1 (en) 2002-04-10 2003-10-23 Eli Lilly And Company Treatment of gastroparesis
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
DE602004025205D1 (de) 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
BR122019021416A2 (https=) 2003-09-19 2019-12-21
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
JP2008502301A (ja) 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ペプチドの抱合
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
US20090117640A1 (en) 2005-08-18 2009-05-07 Novo Nordisk Health Care Ag Transglutaminase Variants with Improved Specificity
JP5486809B2 (ja) 2006-02-14 2014-05-07 ノボ ノルディスク ヘルス ケア アーゲー Ｃ末端におけるポリペプチドの結合
BRPI0713963A2 (pt) 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag conjugados de proteìna e métodos para sua preparação
ES2745411T3 (es) 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
WO2008020075A1 (en) 2006-08-18 2008-02-21 Novo Nordisk Health Care Ag Transglutaminase variants with improved specificity
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
BRPI0716261A2 (pt) 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
US8383852B2 (en) 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008112836A2 (en) 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891840A (en) * 1988-08-24 1999-04-06 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Computational stabilization of human growth hormone;FILIKOV ANTON V等;《PROTEIN SCIENCE》;20020601;第11卷(第6期);1452-1461 *
Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro;ALAM K S M等;《JOURNAL OF BIOTECHNOLOGY》;19981027;第65卷(第2-3期);183-190 *

Also Published As

Publication number Publication date
US20110306548A1 (en) 2011-12-15
WO2010084173A1 (en) 2010-07-29
ZA201105419B (en) 2012-04-25
US8513192B2 (en) 2013-08-20
IL213686A0 (en) 2011-07-31
ES2542202T3 (es) 2015-08-03
AU2010207725A1 (en) 2011-07-21
CN102292349A (zh) 2011-12-21
RU2011133926A (ru) 2013-02-27
CA2747825A1 (en) 2010-07-29
JP5816097B2 (ja) 2015-11-18
RU2539797C2 (ru) 2015-01-27
EP2389389B1 (en) 2015-04-15
MX2011007736A (es) 2011-09-06
EP2389389A1 (en) 2011-11-30
JP2012515748A (ja) 2012-07-12
JP2015193636A (ja) 2015-11-05
TWI504405B (zh) 2015-10-21
AU2010207725B2 (en) 2015-06-11
KR20110122100A (ko) 2011-11-09
TW201032819A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CN102834109B (zh) 稳定的生长激素化合物
US9211342B2 (en) Stable growth hormone compounds resistant to proteolytic degradation
CN102292349B (zh) 稳定的生长激素化合物
US10232020B2 (en) Incretin-insulin conjugates
AU2016365751B2 (en) Use of C-type natriuretic peptide variants to treat osteoarthritis
EP2124974A2 (en) Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP2008543297A (ja) トランスグルタミナーゼを介した成長ホルモンのコンジュゲート
CN105963710A (zh) 具有延长的体内功效的生长激素
US20130143815A1 (en) Growth hormone conjugates
CN101809032A (zh) 用于选择性修饰蛋白质的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant